Category Colon Cancer


Dr. Myers Invited To Share His Research At Preventive Oncology Meeting

Ronald Myers, PhD, Professor of Medical Onocology, was invited to share his work on CRC screening as one of 3 “Best of CEBP” presentations at the recent American Society for Preventive Oncology 39th Annual Meeting in Birmingham, Alabama on March 16, 2015. For more about the ASPO meeting see the agenda  


Phone and Mailed Interventions Significantly Increase Colorectal Cancer Screening Rates

A mailing or phone call to help patients get screened for colorectal cancer significantly increases their chances of actually getting tested, according to a study published in the January issue of Cancer Epidemiology, Biomarkers and Prevention by researchers at the Kimmel Cancer Center at Jefferson. The research team, led by Ronald E. Myers, Ph.D., Professor …


NCI Awards ‘Provocative Questions’ Grant to Thomas Jefferson University Researcher Scott Waldman

Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded one of the prestigious “Provocative Questions”  grants from the National Cancer Institute (NCI) , as part of the Institute’s ambitious program to tackle the “important but not obvious” questions in cancer to ensure no stone …


ASCO: Younger Colon Cancer Patients Have Worse Prognosis at Diagnosis, Yet Better Survival

Younger patients with colorectal cancer were more likely to present advanced stage tumors at diagnosis and metastasize much sooner, yet had better than or equal survival to patients 50 and older, according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, Monday, June 4, 8:00 AM …


Dr. Ronald Myers selected to chair Expert Working Group discussion

Ronald Myers, Ph.D., Professor of Medical Oncology and Director of the Division of Population Science at Thomas Jefferson University, has been selected to chair an Expert Working Group discussion at the World Endoscopy Organization meeting on May 18, 2012. The discussion entitled “Improving Population Engagement in Screening” is being held ahead of the DDW Conference …


Scott Waldman Awarded CURE Grant to Move Colon Cancer Test Closer to Commercialization

Scott Waldman, M.D., Ph.D., Chair of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded a Commonwealth Universal Research Enhancement (CURE) grant for almost $750,000 to help advance a molecular diagnostic test for colon cancer into commercialization. Such a test would better detect recurrence in a group of colon cancer …


Rawls Palmer Progress in Medicine Award Presented to Dr. Scott A. Waldman

Scott A. Waldman, M.D., Ph.D., will receive the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Rawls–Palmer Progress in Medicine Award at the 2012 Annual Meeting on March 16. Established in 1978 by Dr. W. B. Rawls, the award recognizes scientists who have implemented progressive research techniques and tools to improve patient care. ASCPT will …


Stronger Intestinal Barrier May Prevent Cancer in the Rest of the Body, New Study Suggests

A leaky gut may be the root of some cancers forming in the rest of the body, a new study published online Feb. 21 in PLoS ONE by Thomas Jefferson University researchers suggests. It appears that the hormone receptor guanylyl cyclase C (GC-C)—a previously identified tumor suppressor that exists in the intestinal tract—plays a key …


Kimmel Cancer Center at Jefferson Celebrates 20 Years of Patient Care and Cancer Discovery

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who’ve provided an invaluable contribution to medical science and healthcare. “This is truly a milestone for the Kimmel Cancer Center—it’s …


A Tumor Suppressor May Also Fight Obesity

The hormone receptor guanylyl cyclase C (GCC) has been established as a suppressor of colorectal cancer tumors, but new evidence from Thomas Jefferson University suggests it may also help fight one of the country’s biggest pandemics: obesity. Reporting in the August 25 online issue of the Journal of Clinical Investigation, Scott Waldman, M.D., Ph.D., chairman …


Jefferson Clinical Trial: Can a Cholesterol Drug Prevent Colon Cancer?

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer. Previous laboratory research and population studies have shown that patients taking statins, the class of drugs that lowers cholesterol, had fewer colon polyps, …


Shifting a paradigm: A molecular approach to staging colorectal cancer

A quantitative, molecular analysis of lymph nodes in patients deemed colorectal cancer-free was found to be an effective predictor of recurrence, according to a study from researchers at the Kimmel Cancer Center at Jefferson and published online Feb 9. in Clinical Cancer Research. Recurrence occurs in about 25 percent of node-negative patients (pN0), suggesting that …


Giovanni M. Pitari, M.D., Ph.D. receives award from the American Institute for Cancer Research

Giovanni M. Pitari, M.D., Ph.D., has received an award from the American Institute for Cancer Research to support his research project entitled ‘Therapeutic Synergy between Dietary Calcium and Bacterial Enterotoxins for the Prevention and Treatment of Colon Cancer’. The award provides research funding directed toward discovering innovative therapeutic modalities for cancer prevention and cure. Dr. …


Second Annual Get Your Rear In Gear Event

The second annual Philadelphia Get Your Rear In Gear will took  place at 7:30 a.m. on Martin Luther King Drive in Philadelphia, Sunday, March 21, 2010, during National Colorectal Cancer Awareness Month.  Both survivors and those lost to colorectal cancer were honored.  There was a 5K Race  and a 2 mile Remembrance Walk. Results are …


Pre-emptive Treatment Helped Curtail Skin Toxicity with Panitumumab

With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Edith Mitchell, M.D., a clinical professor in the Department of Medical …


African-Americans Have Worse Prognosis Compared to Caucasians When Diagnosed With Colorectal Cancer

African-American patients with colorectal were more likely to present with worse pathological features at diagnosis and to have a worse five-year survival rate compared to Caucasian patients, according to a study conducted by researchers at Thomas Jefferson University. The results are being presented at the 2009 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. …


Different Type of Colon Cancer Vaccine Reduces Disease Spread, Jefferson Scientists Show

Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease. Reporting online Tuesday, June 24, 2008 in the Journal of the National Cancer …